Acute Pyelonephritis Drug Pipeline Analysis Report 2025

Acute pyelonephritis is a bacterial infection of the kidneys, often arising from urinary tract infections. It accounts for around 10.5 million to 25.9 million cases globally each year. There is a significant unmet clinical need for better therapies, as current treatment options, such as antibiotics, often fail to address recurrent infections or antimicrobial resistance. The growing focus on developing novel antibiotics, immunotherapies, and targeted treatments is likely to support pipeline growth in the coming years. Advances in precision medicine and increased research funding are expected to drive innovation and improve treatment outcomes for this condition.

Report Coverage

The Acute Pyelonephritis Drug Pipeline Insight Report by the publisher gives comprehensive insights into acute pyelonephritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute pyelonephritis. The acute pyelonephritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute pyelonephritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute pyelonephritis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute pyelonephritis.

Acute Pyelonephritis Drug Pipeline Outlook

Acute pyelonephritis is a bacterial infection of the kidneys, often caused by the ascending spread of bacteria from the urinary tract. It occurs primarily due to E. coli, although other pathogens can be involved. The disease is characterized by fever, flank pain, and dysuria. Early diagnosis and treatment are critical to preventing complications.

Acute pyelonephritis treatment is primarily done with antibiotics such as ciprofloxacin, trimethoprim-sulfamethoxazole, or ceftriaxone. In severe cases, intravenous antibiotics and hospitalization may be required. However, drug resistance and recurrence are challenges, leading to ongoing research for more effective and targeted therapies in the pipeline.

Acute Pyelonephritis Epidemiology

Pyelonephritis affects an estimated 10.5 million to 25.9 million individuals globally each year. In the United States, the incidence of acute pyelonephritis is 15 to 17 cases per 10,000 adults, with women representing 80% of cases. In Japan, urinary tract infection-related hospitalizations are 6.8 per 10,000 men and 12.4 per 10,000 women, with a 4.5% in-hospital mortality rate. Given the high burden and recurring infections, there is a critical need for more effective and innovative drug treatments.

Acute Pyelonephritis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of acute pyelonephritis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics

By Route of Administration

• Oral
• Parenteral
• Others

Acute Pyelonephritis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total acute pyelonephritis clinical trials.

Acute Pyelonephritis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the acute pyelonephritis pipeline analysis include small molecules and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Acute Pyelonephritis.

Acute Pyelonephritis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The acute pyelonephritis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute pyelonephritis clinical trials:

• Spero Therapeutics
• Rempex
• Wockhardt
• Jiangsu HengRui Medicine Co., Ltd.
• Hamad Medical Corporation
• GlaxoSmithKline
• NeuroRx, Inc.
• Medpace, Inc.
• Evopoint Biosciences Inc.
• Meiji Seika Pharma Co., Ltd.

Acute Pyelonephritis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute pyelonephritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute pyelonephritis drug candidates.

Drug: TBP-PI-HBr

Sponsored by Spero Therapeutics, the objective of this Phase 3 study is to examine the efficacy of oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) compared to intravenous imipenem-cilastatin in participants with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP). The study is expected to be completed by November 2025 and has an estimated 2,648 participants.

Drug: HRS-8427

Sponsored by Jiangsu HengRui Medicine Co., Ltd., a Phase 3 clinical trial is underway to assess the efficacy and safety of HRS-8427 in treating adults with complicated urinary tract infections, including acute pyelonephritis. The study, with around 578 participants, is expected to be completed by November 2025, aiming to provide valuable insights into this potential treatment.

Drug: Meropenem-Vaborbactam

A Phase 2 study sponsored by Rempex (a subsidiary of Melinta Therapeutics, LLC) aims to evaluate the safety, tolerability, and pharmacokinetics of Meropenem-Vaborbactam in children aged 3 months to less than 12 years with complicated urinary tract infections, including acute pyelonephritis. The study is expected to be completed by July 2027, with nearly 66 participants.

Reasons To Buy This Report

The Acute Pyelonephritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for acute pyelonephritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute pyelonephritis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Acute Pyelonephritis - Pipeline Insight Report

• Which companies/institutions are leading the acute pyelonephritis drug development?
• What is the efficacy and safety profile of acute pyelonephritis pipeline drugs?
• Which company is leading the acute pyelonephritis pipeline development activities?
• What is the current acute pyelonephritis commercial assessment?
• What are the opportunities and challenges present in the acute pyelonephritis drug pipeline landscape?
• What is the efficacy and safety profile of acute pyelonephritis pipeline drugs?
• Which company is conducting major trials for acute pyelonephritis drugs?
• Which companies/institutions are involved in acute pyelonephritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in acute pyelonephritis?

This product will be delivered within 3-5 business days.